Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, March 22 '25)

 


    Am J Med

  1. HOLLAND J, Sheehan D, Brown S, O'Flanagan S, et al
    Immune Response and Cognitive Impairment in Post-COVID Syndrome: A Systematic Review.
    Am J Med. 2025;138:698-711.
    PubMed         Abstract available

  2. PASCULLI P, Zingaropoli MA, Dominelli F, Solimini AG, et al
    Insights into Long COVID: Unraveling Risk Factors, Clinical Features, Radiological Findings, Functional Sequelae and Correlations: A Retrospective Cohort Study.
    Am J Med. 2024 Sep 17:S0002-9343(24)00569-2. doi: 10.1016/j.amjmed.2024.
    PubMed         Abstract available

  3. XU J, Wu D, Yang J, Zhao Y, et al
    Adult Outpatients with Long COVID Infected with SARS-CoV-2 Omicron Variant. Part 1: Oral Microbiota Alterations.
    Am J Med. 2025;138:732-741.
    PubMed         Abstract available

  4. YOO KH, Lee SH, Cho Y, Kim YJ, et al
    Synergistic Effect of SARS-CoV-2 Infection and COVID-19 Vaccination on the Risk of Venous Thromboembolism.
    Am J Med. 2025;138:673-680.
    PubMed         Abstract available

  5. MARKSER A, Vockel J, Schneider A, Baumeister-Lingens L, et al
    Non-Invasive Brain Stimulation for Post-COVID-19 Conditions: A Systematic Review.
    Am J Med. 2025;138:681-697.
    PubMed         Abstract available

  6. SAWANO M, Wu Y, Shah RM, Zhou T, et al
    Long COVID Characteristics and Experience: A Descriptive Study From the Yale LISTEN Research Cohort.
    Am J Med. 2025;138:712-720.
    PubMed         Abstract available

  7. SANAL-HAYES NEM, Hayes LD, Mclaughlin M, Berry ECJ, et al
    Post-Traumatic Stress Disorder and Complex Post-Traumatic Stress Disorder in People with Long COVID, ME/CFS, and Controls.
    Am J Med. 2025;138:742-749.
    PubMed         Abstract available


    Arch Virol

  8. ZHANG H, Ouyang S, Qu Y, Li Z, et al
    Humoral immune response characteristics of vulnerable populations against SARS-CoV-2 strains EG.5 and JN.1 after infection with strains BA.5 and XBB.
    Arch Virol. 2025;170:82.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  9. GU L, Wang ZJ, Zhang XR, Liu Y, et al
    Targeting the liquid-liquid phase separation of nucleocapsid broadly inhibits the replication of SARS-CoV-2 strains.
    Biochem Biophys Res Commun. 2025;756:151594.
    PubMed         Abstract available

  10. KOCHAROVSKAYA MV, Pichkur EB, Ivannikov AD, Kharlampieva DD, et al
    Structure and dynamics of Alpha B.1.1.7 SARS-CoV-2 S-protein in complex with Fab of neutralizing antibody REGN10987.
    Biochem Biophys Res Commun. 2025;755:151558.
    PubMed         Abstract available


    BMC Pediatr

  11. BARIDAH I, Setyowireni DK, Citta AN, Arguni E, et al
    The severity of pediatric COVID-19 during hospitalization is not associated with mortality within six months of discharge.
    BMC Pediatr. 2025;25:199.
    PubMed         Abstract available

  12. POURJOULA F, Mirlohi SH, Ghanbari N
    Comparative analysis of croup severity and treatment in pediatric patient: a study of COVID-19 positive vs. negative cases during peak Omicron.
    BMC Pediatr. 2025;25:194.
    PubMed         Abstract available


    Cell

  13. JIANG S, Wu F
    Global surveillance and countermeasures for ACE2-using MERS-related coronaviruses with spillover risk.
    Cell. 2025;188:1465-1468.
    PubMed         Abstract available

  14. CHEN J, Zhang W, Li Y, Liu C, et al
    Bat-infecting merbecovirus HKU5-CoV lineage 2 can use human ACE2 as a cell entry receptor.
    Cell. 2025;188:1729-1742.
    PubMed         Abstract available


    Epidemiol Infect


  15. Are children and adolescents living with HIV in Europe and South Africa at higher risk of SARS-CoV-2 and poor COVID-19 outcomes?
    Epidemiol Infect. 2025;153:e44.
    PubMed         Abstract available


    J Exp Med

  16. GROEN K, Kuratli R, Enkelmann J, Fernbach S, et al
    Type I interferon autoantibody footprints reveal neutralizing mechanisms and allow inhibitory decoy design.
    J Exp Med. 2025;222:e20242039.
    PubMed         Abstract available


    J Immunol

  17. RAO AS, Ugwu N, Onufer AP, Kumova O, et al
    Cathelicidin-related antimicrobial peptide (CRAMP) is toxic during neonatal murine influenza virus infection.
    J Immunol. 2025 Mar 18:vkae053. doi: 10.1093.
    PubMed         Abstract available


    J Infect

  18. ZHAO J, Sheng G, Lyu Y, Sun Y, et al
    Oral ADC189 for Adults and Adolescents with Uncomplicated Influenza.
    J Infect. 2025 Mar 13:106472. doi: 10.1016/j.jinf.2025.106472.
    PubMed         Abstract available


    J Infect Dis

  19. WONG JY, Cheung JK, Presanis AM, De Angelis D, et al
    Assessing the impact of influenza epidemics in Hong Kong.
    J Infect Dis. 2025 Mar 19:jiaf140. doi: 10.1093.
    PubMed         Abstract available

  20. QUACH HQ, Goergen KM, Grill DE, Ovsyannikova IG, et al
    IL-8 as a Causal Link Between Aging and Impaired Influenza Antibody Responses in Older Adults.
    J Infect Dis. 2025 Mar 17:jiaf148. doi: 10.1093.
    PubMed         Abstract available

  21. WANG J, Genberg BL, Feder K, Kirk GD, et al
    Impact of pandemic-induced service disruptions and behavioral changes on HCV and HIV transmission amongst people who inject drugs: a modeling study.
    J Infect Dis. 2024 Dec 6:jiae599. doi: 10.1093.
    PubMed         Abstract available

  22. MENG Y, Lin Y, Xiong W, Lau EHY, et al
    Effective Real-time Transmission Estimations Incorporating Population Viral Load Distributions Amid SARS-CoV-2 Variants and Preexisting Immunity.
    J Infect Dis. 2025;231:684-691.
    PubMed         Abstract available

  23. MADHI SA, Simoes EAF, Acevedo A, Novoa Pizarro JM, et al
    A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants.
    J Infect Dis. 2025;231:e478-e487.
    PubMed         Abstract available

  24. THAMBI N, Phuah JY, Staupe RP, Tobias LM, et al
    Development of High-Titer Antidrug Antibodies in a Phase 1b/2a Infant Clesrovimab Trial Are Associated With RSV Exposure Beyond Day 150.
    J Infect Dis. 2025;231:e488-e496.
    PubMed         Abstract available

  25. PROBOSTE T, Bista D, Clark NJ, Arora S, et al
    Ascertainment of Community Exposure Sites to Ross River Virus During the 2020 Outbreak in Brisbane, Australia.
    J Infect Dis. 2025;231:e501-e510.
    PubMed         Abstract available

  26. MAK J, Khan S, Britton A, Rose S, et al
    Association of mRNA COVID-19 vaccination and reductions in Post-COVID Conditions following SARS-CoV-2 infection in a US prospective cohort of essential workers.
    J Infect Dis. 2024 Nov 13:jiae556. doi: 10.1093.
    PubMed         Abstract available

  27. WINKEL AMAM, Kozanli E, Haverkort ME, Euser SM, et al
    Lower Levels of Household Transmission of SARS-CoV-2 Omicron Variant of Concern vs Wild Type: An Interplay Between Transmissibility and Immune Status.
    J Infect Dis. 2025;231:653-664.
    PubMed         Abstract available

  28. REILLY C, Mylonakis E, Dewar R, Young B, et al
    Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019.
    J Infect Dis. 2025;231:677-683.
    PubMed         Abstract available

  29. MONTO AS, Foster-Tucker JE, Callear AP, Leis AM, et al
    Respiratory Viral Infections From 2015 to 2022 in the HIVE Cohort of American Households: Incidence, Illness Characteristics, and Seasonality.
    J Infect Dis. 2025;231:795-804.
    PubMed         Abstract available


    J Virol

  30. FURUSAWA Y, Kiso M, Uraki R, Sakai-Tagawa Y, et al
    Amino acid substitutions in NSP6 and NSP13 of SARS-CoV-2 contribute to superior virus growth at low temperatures.
    J Virol. 2025 Feb 12:e0221724. doi: 10.1128/jvi.02217.
    PubMed         Abstract available

  31. KUHN AJ, Outlaw VK, Marcink TC, Yu Z, et al
    Enhancing the solubility of SARS-CoV-2 inhibitors to increase future prospects for clinical development.
    J Virol. 2025 Feb 4:e0215924. doi: 10.1128/jvi.02159.
    PubMed         Abstract available

  32. PHAN T, Ribeiro RM, Edelstein GE, Boucau J, et al
    Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance.
    J Virol. 2025 Feb 4:e0162324. doi: 10.1128/jvi.01623.
    PubMed         Abstract available

  33. SAMAAN P, Korosec CS, Budylowski P, Chau SLL, et al
    mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-gamma and IL-2 T-cell responses are predictive of serological neutralization and are transiently enhanced by pre-existing cross-reactive immunity.
    J Virol. 2025 Jan 31:e0168524. doi: 10.1128/jvi.01685.
    PubMed         Abstract available

  34. WANG X, Dong M, Wu X, Schnepf D, et al
    Single-cell transcriptomics reveals a compartmentalized antiviral interferon response in the nasal epithelium of mice.
    J Virol. 2025 Feb 4:e0141324. doi: 10.1128/jvi.01413.
    PubMed         Abstract available

  35. MA R, Zhang X, Li R, Dong X, et al
    PLSCR1 suppresses SARS-CoV-2 infection by downregulating cell surface ACE2.
    J Virol. 2025 Feb 13:e0208524. doi: 10.1128/jvi.02085.
    PubMed         Abstract available

  36. BEAVIS AC, Li Z, Briggs K, Gingerich MC, et al
    Efficacy of parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine as a single dose primer and booster against SARS-CoV-2 variants.
    J Virol. 2025 Mar 21:e0198924. doi: 10.1128/jvi.01989.
    PubMed         Abstract available

  37. BEAVIS AC, Xiao P, Gingerich MC, Briggs K, et al
    A parainfluenza virus 5 (PIV5)-vectored intranasal SARS-CoV-2 vaccine (CVXGA1) elicits protective and long-lasting immunity in nonhuman primates.
    J Virol. 2025 Mar 21:e0199024. doi: 10.1128/jvi.01990.
    PubMed         Abstract available


    PLoS Comput Biol

  38. EALES O, Shearer FM, McCaw JM
    How immunity shapes the long-term dynamics of influenza H3N2.
    PLoS Comput Biol. 2025;21:e1012893.
    PubMed         Abstract available


    PLoS One

  39. BAAKLINY M, Ghosn N, Saleh N, Maison P, et al
    Effectiveness of the Pfizer-BioNTech (BNT162b2) vaccine against the omicron variant of SARS-CoV-2 among adults aged 50 and above: A case-control study in Lebanon, June 2022.
    PLoS One. 2025;20:e0318344.
    PubMed         Abstract available

  40. VICENCIO VV, Viengkham C, Grange N, Norton S, et al
    COVID-19 outbreak management in Western Sydney residential aged care homes: A mixed-methods Donabedian evaluation.
    PLoS One. 2025;20:e0318490.
    PubMed         Abstract available

  41. PHIRI MM, Dunkley Y, Di Giacomo E, Lora W, et al
    Factors influencing uptake of COVID-19 diagnostics in Sub-Saharan Africa: a rapid scoping review.
    PLoS One. 2025;20:e0305512.
    PubMed         Abstract available

  42. STRINGER WS, Labar AS, Geleris JD, Sholle EV, et al
    Three hospitalized non-critical COVID-19 subphenotypes and change in intubation or death over time: A latent class analysis with external and longitudinal validation.
    PLoS One. 2025;20:e0316434.
    PubMed         Abstract available

  43. SUWANAI H, Kanda M, Harada K, Ishii K, et al
    Diabetes with COVID-19 was a significant risk factor for mortality, mechanical ventilation, and renal replacement therapies: A multicenter retrospective study in Japan.
    PLoS One. 2025;20:e0319801.
    PubMed         Abstract available

  44. MIRANDA AR, Scotta AV, Cortez MV, Soria EA, et al
    Two-years mothering into the pandemic: Impact of the three COVID-19 waves in the Argentinian postpartum women's mental health.
    PLoS One. 2025;20:e0294220.
    PubMed         Abstract available

  45. PADILLA S, Andreo M, Marco P, Marco-Rico A, et al
    Enhanced prediction of thrombotic events in hospitalized COVID-19 patients with soluble thrombomodulin.
    PLoS One. 2025;20:e0319666.
    PubMed         Abstract available

  46. HO T, Lailo JM, Ramoran E, Mutreja K, et al
    Leveraging a digital network of pharmacy professionals to test a technology-assisted model to improve pharmacy access to quality-assured COVID-19 rapid antigen tests approved for self-use in Vietnam.
    PLoS One. 2025;20:e0318331.
    PubMed         Abstract available

  47. CARDOSO CO, Rodrigues Sandoval ES, de Oliveira Chagas LBM, Badra SJ, et al
    Neurologic manifestations of COVID-19 and viral test in cerebrospinal fluid.
    PLoS One. 2025;20:e0312621.
    PubMed         Abstract available

  48. TAYLOR-ABDULAI HB, Dzantor EK, Mensah NK, Asumah MN, et al
    Coronavirus disease 2019 (COVID-19) vaccine acceptability in Ghana: An urban-based population study.
    PLoS One. 2025;20:e0319798.
    PubMed         Abstract available

  49. MALTESE C, Gandhi CK, Ramirez SI, Sznajder KK, et al
    Access to lactation consult services during the COVID-19 pandemic and the impact on breastfeeding outcome variables.
    PLoS One. 2025;20:e0318749.
    PubMed         Abstract available

  50. HAMADANI JD, Bhuiyan SA, Hasan MI, Grantham-McGregor S, et al
    The effect of exposure to the COVID-19 pandemic on nutritional status and cognitive, motor, and behavioural development among children aged 20 months in rural Bangladesh: A repeated cross-section study between 2020 and 2022.
    PLoS One. 2025;20:e0309836.
    PubMed         Abstract available

  51. MUHAMAD NA, Ma'amor NH, Jamalluddin NH, Rosli IA, et al
    Technostress and its associated factors: Burnout and fatigue among Malaysian healthcare workers (HCWs) in state hospitals.
    PLoS One. 2025;20:e0319506.
    PubMed         Abstract available

  52. PEREIRA AMM, Esperidiao MA, Andrade SKAV, Silva JFM, et al
    Governance and responses of health and surveillance systems to COVID-19 in BRICS countries: A scoping review protocol.
    PLoS One. 2025;20:e0319572.
    PubMed         Abstract available

  53. GU Z, Luo X, Sun R, Xi T, et al
    Long-term effects of the COVID-19 lockdown on the structural and functional outcomes of neovascular AMD patients in Suzhou, China.
    PLoS One. 2025;20:e0319677.
    PubMed         Abstract available

  54. AGHA S, Nazir S, Kaleem M, Najeeb F, et al
    Performance evaluation of reduced complexity deep neural networks.
    PLoS One. 2025;20:e0319859.
    PubMed         Abstract available

  55. HARUN SNF, Jasman N, Mustapha F, Jaafar N, et al
    Noteworthy trends in maladaptive coping strategies and hindrances to help-seeking behaviour among adolescents living in Malaysia's People's Housing Project (PPR) during the COVID-19 pandemic: A qualitative study.
    PLoS One. 2025;20:e0318381.
    PubMed         Abstract available

  56. GRANADOS SAMAYOA JA, Moore CA, Ruisch BC, Ladanyi JT, et al
    Is there anything good about conspiracy beliefs? Belief in COVID-19 conspiracy theories is associated with benefits to well-being.
    PLoS One. 2025;20:e0319896.
    PubMed         Abstract available

  57. OUAKOUAK ML, Ouedraogo N, Hewapathirana GI, Zaitouni M, et al
    Role of leaders' positive mindset in mitigating the effects of crises on organizations: The case of Canadian organizations.
    PLoS One. 2025;20:e0319931.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  58. DOS S P ANDRADE AC, Lacasse E, Dubuc I, Gudimard L, et al
    Deficiency in platelet 12-lipoxygenase exacerbates inflammation and disease severity during SARS-CoV-2 infection.
    Proc Natl Acad Sci U S A. 2025;122:e2420441122.
    PubMed         Abstract available

  59. EILERSEN A, Bjornstad ON, Li R, Schreiber SJ, et al
    Epidemic evolutionarily stable strategies within an age-structured host population.
    Proc Natl Acad Sci U S A. 2025;122:e2418170122.
    PubMed         Abstract available

  60. GAILLETON R, Mathew NR, Reusch L, Schon K, et al
    Ectopic germinal centers in the nasal turbinates contribute to B cell immunity to intranasal viral infection and vaccination.
    Proc Natl Acad Sci U S A. 2025;122:e2421724122.
    PubMed         Abstract available


    Vaccine

  61. PATTHAMMAVONG C, Wodniak N, Phounphenghack K, Tengbriacheu C, et al
    Factors associated with influenza and COVID-19 vaccination among health workers in Lao PDR, 2023.
    Vaccine. 2025;54:127006.
    PubMed         Abstract available

  62. HEGMANN TE, Walter EB, Smith MJ, Campbell J, et al
    A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone(R) or Flublok(R)) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age.
    Vaccine. 2025;54:126991.
    PubMed         Abstract available

  63. THORS V, Vias RD, Bjornsdottir K, Palsdottir EB, et al
    Influenza vaccine effectiveness in Iceland 2014-2022: A test-negative design.
    Vaccine. 2025;55:126981.
    PubMed         Abstract available


    Virologie (Montrouge)

  64. CAVARELLI M
    Ghosts of the virus : unmasking the persistent threat of SARS-CoV-2 in Long COVID.
    Virologie (Montrouge). 2025;29:57-68.
    PubMed         Abstract available

  65. CAVARELLI M
    [Ghosts of the virus : unmasking the persistent threat of SARS-CoV-2 in Long COVID].
    Virologie (Montrouge). 2025;29:41-53.
    PubMed         Abstract available


    Virology

  66. BENLARBI M, Kenfack DD, Dionne K, Cote-Chenette M, et al
    Longitudinal humoral immunity against SARS-CoV-2 Spike following infection in individuals from Cameroon.
    Virology. 2025;605:110467.
    PubMed         Abstract available

Comments

Popular posts from this blog

#USA, APHIS Confirms {Avian #Influenza #H5N1} #D11 #Genotype in Dairy #Cattle in #Nevada

On January 31, 2025, the USDA Animal and Plant Health Inspection Service (APHIS) National Veterinary Services Laboratories (NVSL) confirmed by whole genome sequence the first detection of highly pathogenic avian influenza (HPAI) H5N1 clade 2.3.4.4b, genotype D1.1 in dairy cattle .  This confirmation was a result of State tracing and investigation, following an initial detection on silo testing under the USDA’s National Milk Testing Strategy (NMTS) in Nevada.  USDA APHIS continues to work with the Nevada Department of Agriculture by conducting additional on-farm investigation, testing, and gathering additional epidemiological information to better understand this detection and limit further disease spread.  This is the first detection of this virus genotype in dairy cattle (all previous detections in dairy cattle have been HPAI H5N1 clade 2.3.4.4b, genotype B3.13 ).  Genotype D1.1 represents the predominant genotype in the North American flyways this past fall an...

#USA, After #Birdflu Detected in Local #Cat, County #Health Officials Say #Pet Owners Should Contact Veterinarian When Their Pets are Sick

Redwood City — State veterinary and health officials have confirmed a case of H5N1 (bird flu) in a domestic stray cat in San Mateo County.  The infection, which is not related to the recent instance of bird flu in a backyard flock , was found in a stray cat in Half Moon Bay that had been taken in by a family .  When it showed symptoms, they took it to Peninsula Humane Society, whose veterinarians examined it and requested testing. Lab results confirmed H5N1.  It is not known how the cat was infected and it was euthanized due to its condition. Cats may be exposed to bird flu by consuming infected bird , being in environments contaminated with the virus and consuming unpasteurized milk from infected cows or raw food. Inside domestic animals, such as cats and dogs, that go outside are also at risk of infection.​​​​​​​ According to the Centers for Disease Control and Prevention, the risk of cats spreading H5N1 to people is extremely low, though it is possible for cats to spre...

#USA, Novel #Influenza A #H5N1 Virus: One Pediatric Case in #California {FluView}

 {Excerpt} One confirmed human infection with influenza A(H5) virus was reported to CDC this week. To date, human-to-human transmission of influenza A(H5) virus has not been identified in the United States. This case was reported by the California Department of Public Health and occurred in a child less than 18 years old with no known contact with influenza A(H5N1) virus-infected animals or humans . The investigation into the source of infection for this case is ongoing , and no human-to-human transmission has been identified. A specimen from the individual was tested at a public health laboratory using the CDC influenza A(H5) assay before being sent to CDC for further testing. The specimen was positive for influenza A(H5) virus using diagnostic RT-PCR at CDC. Additional analysis including genetic sequencing is underway. In response to this detection, additional case investigation and contact monitoring are being conducted by public health officials in California. There have now be...